Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Cash Flow (2020 - 2025)

Arcutis Biotherapeutics has reported Net Cash Flow over the past 6 years, most recently at -$4.3 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$4.3 million for Q4 2025, up 93.25% from a year ago — trailing twelve months through Dec 2025 was -$28.9 million (down 68.68% YoY), and the annual figure for FY2025 was -$28.9 million, down 68.68%.
  • Net Cash Flow for Q4 2025 was -$4.3 million at Arcutis Biotherapeutics, up from -$25.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for ARQT hit a ceiling of $223.6 million in Q1 2021 and a floor of -$199.6 million in Q2 2021.
  • Median Net Cash Flow over the past 5 years was -$6.3 million (2022), compared with a mean of -$1.2 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 931.49% in 2021 and later surged 1975.78% in 2024.
  • Arcutis Biotherapeutics' Net Cash Flow stood at $44.7 million in 2021, then crashed by 162.46% to -$27.9 million in 2022, then soared by 31.4% to -$19.1 million in 2023, then plummeted by 230.61% to -$63.3 million in 2024, then skyrocketed by 93.25% to -$4.3 million in 2025.
  • The last three reported values for Net Cash Flow were -$4.3 million (Q4 2025), -$25.5 million (Q3 2025), and $19.1 million (Q2 2025) per Business Quant data.